HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA promotes OTC safety

This article was originally published in The Tan Sheet

Executive Summary

United Health Foundation is teaming with FDA on a national health education campaign designed to promote safe use of OTCs. Targeted to women ages 25-60, print ads include a Q&A reminding OTC users to read and follow directions, avoid taking products with the same active ingredient and consult healthcare professionals in the event of side effects. The ads will appear in magazines such as People, Good Housekeeping and Ebony, as well as online news sources Yahoo!, AOL and ABCNews.com. The campaign echoes an OTC safety initiative launched by the agency last year (1"The Tan Sheet" Jan. 26, 2004, p. 8)...

You may also be interested in...

FDA Analgesic Safety Campaign Launches; Label Warnings Still In Progress

FDA launched a public educational campaign Jan. 22 warning consumers about the link between acetaminophen and liver damage, and potential renal and gastrointestinal problems associated with nonsteroidal anti-inflammatory use

Formycon Chief Sees COVID-19 Boosting Biosimilars

Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.

PDUFA Renewal Negotiations: What Does Industry Want Now?

With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts